Approval Background

The EMA granted full marketing authorization for ranibizumab (Rimmyrah) on January 5, 2024. This approval is based on clinical data demonstrating the drug's safety and efficacy. Regulatory authorities aim to expand treatment options for patients based on this data.

Clinical Evidence

Clinical trials showed that ranibizumab had a significant effect on maintaining vision compared to existing treatments. The drug also exhibited a favorable safety profile with low rates of major adverse events. Clinical trials are essential for evaluating the efficacy and risks of new drugs when applied to real-world patients.

Positioning Against Competing Drugs

Ranibizumab aims to differentiate itself from existing ranibizumab-based treatments through price competitiveness or ease of administration. It will directly compete with existing products like Lucentis, making market share acquisition a key challenge. Successful differentiation will provide a new option in the European ophthalmology market.

Reimbursement and Market Access Challenges

European health authorities evaluate drug prices and cost-effectiveness to determine reimbursement eligibility. Therefore, price negotiations and local health technology assessments will be crucial for ranibizumab to be included in reimbursement lists. Reimbursement approval will significantly impact the drug's market entry speed and sales volume.